4519.T
CHUGAI PHARMACEUTICAL CO.,LTD.
プライム · 医薬品 · 医薬品 · JP
JPY 6,878.00
+0.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1291.2B | 1257.9B | 1170.6B | 1111.4B | 1259.9B |
| Cost of Revenue | 92.8B | 363.7B | 339.4B | 413.3B | 476.3B |
| Gross Profit | 229.0B | 894.3B | 831.2B | 698.1B | 783.7B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 28.9B | 116.5B | 110.1B | 112.6B | — |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 2.1B |
| Total Operating Expenses | 28.9B | 116.5B | 110.1B | 112.6B | 2.1B |
| Cost and Expenses | 670.3B | 659.1B | 628.6B | 672.2B | 726.6B |
| Operating Income (EBIT) | 620.9B | 598.8B | 542.0B | 439.2B | 533.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | (42.0M) | 207.0M | (5.0M) | 27.0M | 61.0M |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 160.2B | 597.8B | 543.0B | 443.8B | 531.2B |
| Income Tax Expense | 44.8B | 163.8B | 155.7B | 118.3B | 156.7B |
| Bottom Line | |||||
| Net Income | 452.2B | 434.0B | 387.3B | 325.5B | 374.4B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 452.2B | 434.0B | 387.3B | 325.5B | 374.4B |
| Per Share | |||||
| Basic EPS | ¥275 | ¥264 | ¥235 | ¥198 | ¥228 |
| Diluted EPS | ¥275 | ¥264 | ¥235 | ¥198 | ¥228 |
| Revenue Per Share | ¥785 | ¥764 | ¥711 | ¥676 | ¥766 |
| Shares | |||||
| Basic Shares Outstanding | 1.6B | 1.6B | 1.6B | 1.6B | 1.6B |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | — | — | — | — |
| D&A | — | — | — | — | — |
| EBIT | 620.9B | 598.8B | 542.0B | 439.2B | 533.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026